Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Oric Pharmaceuticals, Inc. Common Stock (ORIC)

Pharmaceutical Preparations

https://www.oricpharma.com

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

240 E. GRAND AVE., 2ND FLOOR
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/24/2020

Market Cap

662,041,363

Shares Outstanding

54,550,000

Weighted SO

54,551,869

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

SEER --.--%

ANEB --.--%

CGEM --.--%

CCCC --.--%

MOLN --.--%

MLYS --.--%

ANTX --.--%

PHVS --.--%

Beta

1.1170

Last Div

0.0000

Range

5.27-16.65

Chg

-1.4450

Avg Vol

578658

Mkt Cap

662041363

Exch

NASDAQ

Country

US

Phone

650 388 5600

DCF Diff

9.3140

DCF

0.2560

Div Yield

0.0000

P/S

430.4560

EV Multiple

-4.9359

P/FV

2.1833

Div Yield %

0.0000

P/E

-5.9596

PEG

-0.3933

Payout

0.0000

Current Ratio

15.0775

Quick Ratio

15.0775

Cash Ratio

2.5503

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

800.3656

CCC

-800.3656

Gross Margin

0.3153

Op Margin

-81.3505

Pretax Margin

-72.0299

Net Margin

-72.0299

Eff Tax Rate

-0.0174

ROA

-0.3368

ROE

-0.4019

ROCE

-0.4044

NI/EBT

1.0000

EBT/EBIT

0.8854

EBIT/Rev

-81.3505

Debt Ratio

0.0084

D/E

0.0092

LT Debt/Cap

0.0000

Total Debt/Cap

0.0091

Int Coverage

-62.9995

CF/Debt

-36.1448

Equity Multi

1.0877

Rec Turnover

0.0000

Pay Turnover

0.4560

Inv Turnover

0.0000

FA Turnover

0.5344

Asset Turnover

0.0047

OCF/Share

-1.4232

FCF/Share

-1.4330

Cash/Share

4.0713

OCF/Sales

-65.0982

FCF/OCF

1.0068

CF Coverage

-36.1448

ST Coverage

-36.1448

CapEx Coverage

-146.1620

Div&CapEx Cov

-146.1620

P/BV

2.1833

P/B

2.1833

P/S

430.4560

P/E

-5.9596

P/FCF

-6.5675

P/OCF

-6.5942

P/CF

-6.5942

PEG

-0.3933

P/S

430.4560

EV Multiple

-4.9359

P/FV

2.1833

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 06, 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Oct 04, 20:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Jan 22, 08:30 ORIC Pharmaceuticals Announces $125 Million Private Placement Financing GlobeNewswire Inc. Jan 02, 16:30 ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Benzinga Dec 13, 12:00 Where ORIC Pharmaceuticals Stands With Analysts GlobeNewswire Inc. Dec 01, 16:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 03, 16:30 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Revenue Product Segmentation